Silk Road Medical, Inc (NASDAQ:SILK) Shares Purchased by Bamco Inc. NY

Bamco Inc. NY lifted its stake in Silk Road Medical, Inc (NASDAQ:SILK) by 28.0% during the 1st quarter, HoldingsChannel.com reports. The fund owned 1,500,170 shares of the company’s stock after purchasing an additional 328,114 shares during the quarter. Bamco Inc. NY’s holdings in Silk Road Medical were worth $27,483,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its stake in Silk Road Medical by 4.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 34,905 shares of the company’s stock worth $640,000 after buying an additional 1,490 shares during the period. Capital World Investors increased its stake in Silk Road Medical by 4.9% during the 1st quarter. Capital World Investors now owns 3,111,730 shares of the company’s stock worth $57,007,000 after buying an additional 145,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its stake in Silk Road Medical by 59.0% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 353,000 shares of the company’s stock worth $6,467,000 after buying an additional 131,000 shares during the period. Vanguard Group Inc. increased its stake in Silk Road Medical by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 2,922,495 shares of the company’s stock worth $53,540,000 after buying an additional 30,726 shares during the period. Finally, First Eagle Investment Management LLC purchased a new stake in Silk Road Medical during the 1st quarter worth approximately $1,605,000.

Analyst Ratings Changes

Several equities research analysts recently weighed in on SILK shares. Argus downgraded shares of Silk Road Medical from a “buy” rating to a “sell” rating in a research note on Thursday, July 11th. Stifel Nicolaus reissued a “hold” rating and issued a $27.50 price objective (up from $23.00) on shares of Silk Road Medical in a research report on Wednesday, July 17th. JPMorgan Chase & Co. increased their price objective on shares of Silk Road Medical from $19.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, May 1st. Lake Street Capital reissued a “hold” rating and issued a $27.50 price objective (down from $28.00) on shares of Silk Road Medical in a research report on Tuesday, June 18th. Finally, Piper Sandler increased their price objective on shares of Silk Road Medical from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, May 1st. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $21.50.

Silk Road Medical Stock Up 0.0 %

Shares of Silk Road Medical stock traded up $0.01 during trading hours on Friday, hitting $27.02. The company had a trading volume of 1,077,613 shares, compared to its average volume of 1,237,167. The company’s 50-day moving average is $24.75 and its two-hundred day moving average is $19.94. Silk Road Medical, Inc has a twelve month low of $6.08 and a twelve month high of $27.19. The company has a debt-to-equity ratio of 0.52, a current ratio of 11.05 and a quick ratio of 9.62. The company has a market cap of $1.07 billion, a P/E ratio of -19.72 and a beta of 1.52.

Silk Road Medical (NASDAQ:SILK) last issued its quarterly earnings results on Tuesday, April 30th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.04. The firm had revenue of $48.50 million during the quarter, compared to analysts’ expectations of $44.67 million. Silk Road Medical had a negative net margin of 29.02% and a negative return on equity of 35.47%. Silk Road Medical’s quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.43) EPS. Analysts anticipate that Silk Road Medical, Inc will post -1.43 earnings per share for the current fiscal year.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.